As the CEO of Rinat Maksyutov center for research selected three promising drug.
MOSCOW, may 26. /TASS/. State research center of Virology and biotechnology “Vector” of Rospotrebnadzor plans to begin clinical trials of a vaccine against new coronavirus infection in late June to study selected three promising drug. In an interview with TASS the General Director of the Rinat Maksyutov.
In April native at a meeting with Russian President Vladimir Putin on the development of the situation with coronavirus infection reported that “Vector” is ready to proceed to phase I clinical studies of the vaccine in may with the permission of the Ministry of health. The Minister of health of the Russian Federation Mikhail Murashko then said that it is possible.
“In accordance with the approved program of the clinical study will begin on 29 June 2020 after the results of specific activity and safety of vaccines in animals and obtaining permission of the Ministry of health of Russia. While we are working in the framework of our schedule,” — said the native.
the General Director of “Vector” also said that on sensitive animal study was conducted of 25 different vaccines. “Three promising formulation was selected as showing the highest efficiency, and also considering technological requirement of large-scale production,” he added.
In Russia, according to the Federal operative headquarters of the anti-coronavirus, was 353 427 cases of infection, recovered 118 798 people died 3 633.
